News

Teva Pharmaceutical Industries Ltd. announced that it has received regulatory approval from the European Commission for its acquisition of Allergan plc’s global generics business. As part of the approval, Teva has agreed to the divestment of...

Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners today announced the formation of Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gynecologic diseases and disorders. In exchange for undisclosed...

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and TR-Pharm announced today a strategic collaboration agreement involving 3 biosimilar products. A total of three products will be registered and subsequently commercialized as a part of this agreement...

H. Lundbeck A/S announced that the investigational compound Lu AF35700, a novel antipsychotic, is entering clinical phase III program. Lundbeck is initiating the phase III program which is currently planned to consist of two pivotal trials....

Irritable bowel syndrome (IBS) refers to a complex disorder of the lower intestinal tract. It is mainly characterized by a pattern of symptoms that is often worsened by emotional stress. It is not the same as inflammatory bowel disease...

Bayer is committed to delivering sustainable agricultural solutions to overcome today’s challenges and contribute towards meeting the sustainable development goals of the United Nations. At this year’s Fruit Logistica in Berlin from February 3 to 5, the company presented...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the company’s investigational...